Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$PCTL Update today 1pm: PCT’s Expansion into Cannabis Market
The firm will post its podcast on PCT’s solutions for plant diseases.
https://twitter.com/PCTL_/status/1696177837131153621?s=20
$PCTL
GM. I enjoy MBB but don‘t appreciate negativity from haters.
Please remove #2323189 by a stalker going board-to-board.
I like MBB for sharing ticker updates vs. stalker harassment.
The hater had a “Violation of Privacy” ban and is still pissed.
Please remove #2323189 as OT. I enjoy MBB but not haters.
Feel free to board-ban this known stalker and harasser from
your private MBB board as he contributes hate and garbage.
A check of his negative history shows a hate for OTC stocks.
I would like to continue contributing positive posts to MBB as
often as possible. Feel free to remove my msg afterward. TY
Imagine being the guy who bought in 20‘s to 30’s RIP. This is
in a downtrend. Watered down its price or shorters in control?
$PCTL Fighting Hop Latent Viroid in Cannabis Operations
Wed 8/30/23 https://pctl.com/podcast on Cannabis Update
https://pctl.com/newsroom/fighting-hop-latent-viroid-in-cannabis-operations/
https://twitter.com/PCTL_/status/1696177837131153621?s=20
$PCTL Fighting Hop Latent Viroid in Cannabis Operations
Wed 8/30/23 https://pctl.com/podcast on Cannabis Update
https://pctl.com/newsroom/fighting-hop-latent-viroid-in-cannabis-operations/
https://twitter.com/PCTL_/status/1696177837131153621?s=20
$PCTL Update on PCT’s Expansion into Cannabis Market
The company update on PCT’s solution for plant diseases
https://twitter.com/PCTL_/status/1696177837131153621?s=20
$PCTL
$PCTL Update on PCT’s Expansion into Cannabis Market
The company update on PCT’s solution for plant diseases
https://twitter.com/PCTL_/status/1696177837131153621?s=20
$PCTL
Hittin’ 13s today? DWAC‘d again. My oh my.
Its big red slippy slide from spring continues.
Writings on the wall is: Down it goes further.
What? Naked shorts? Yikes!
Don’t they drive things down?
Noticed the 004s lows earlier.
$PCTL Update on PCT’s Expansion into Cannabis Market
The company update on PCT’s solution for plant diseases
https://twitter.com/PCTL_/status/1696177837131153621
$PCTL
$PCTL Update on PCT’s Expansion into Cannabis Market
The company update on PCT’s solution for plant diseases
https://twitter.com/PCTL_/status/1696177837131153621
$PCTL
DBMM historic charts showing August bottoms in .004s,
.0045s after August p&d‘s. Anything to break the cycle?
Apart from little p&d’s DWAC’ked big red slide
continues! Check 1-year chart. 5-year is eww!
Once mugshot T’s bucks run out, any luck too.
Sell DWAC’ked for coin… or take any tax loss.
Yet another NT-10 filed. Is BSF lost in the
Brazilian jungles? Make the bird call! Lol!
https://www.otcmarkets.com/filing/html?id=16864592&guid=VaN-kK1DvC9pJth
Time to send out the search party. GDSI
won their case but searching for $Reals?
So richme, dump side of the recent pump?
Looks like your prediction has some teeth.
Awesome you got some bank from selling.
The best is yet to come. That's $10 and less.
DWAC grifters are grifting again.
Funds for legal attorneys,
for criminals, and
canaries.
Sad.
louisforpar, is that like the double orange clause?
Ya know…like an orange shirt and trousers? Lol.
Maybe da DWAC’ked grifted with buy him an a/c?
I hear it can get awfully stuffy in Georgia prisons.
The gritty grifts got mugged.
Smile for da camera.
DWAC’d again.
How sad.
Lol.
DWAC’ked again: Georgia Capital Punishment Laws: Treason
FindLaw, Legally Reviewed, Fact-Checked
“Although some states have abolished the practice, Georgia and most other states continue to use capital punishment (the death penalty) as a sentence for some of the most serious crimes. Georgia capital punishment law may be applied to defendants 17 and older for certain homicides (including those involving rape, armed robbery, or against a peace officer, for example), as well as for airplane hijacking or treason.”
Hitting 12s at opening? DWAC‘d again. My oh my.
Red DWAC’ked slippy slide from spring continues.
The gritty grifts got mugged.
Smile for da camera.
DWAC’d again.
How sad.
Lol.
Hitting 12s tomorrow? DWAC‘d again. My oh my.
That big red slippery slide from spring continues.
Closing 12s today? DWAC‘d again. My oh my.
The big red slippy slide from spring continues.
Revealing interview...
Former board member Grifter-In-Chief is DWAC’d again...
You haven't heard...
The Grifter-In-Chief and his ilk are DWAC’ked again.
Servicemen & veterans aren’t “suckers” and “losers”.
Meanwhile, DWAC is down since its spring p&d run.
Hitting 13’s today. DWAC‘d again. My oh my.
Its big red slippy slide from spring continues.
Kissing 13’s today. DWAC‘d again. My oh my.
The big red slippy slide from spring continues.
Agreed. Early Aug. was sweet, late Aug. bitter.
Gotta go after the low-hanging fruit, then book.
Hmm every little rally stopped after the p&d.
Guess we’ll see what its flippers do this fall.
FALSE...... Stop pumping
$TTOO T2Bacteria® FDA clearance could hit anytime
or any day followed by contracts for purchase and use.
Check them out: https://www.t2biosystems.com/news/
or products at: https://www.t2biosystems.com/about-t2/
$TTOO
$TTOO T2Bacteria® FDA clearance could hit anytime
or any day followed by contracts for purchase and use.
Check them out: https://www.t2biosystems.com/news/
or products at: https://www.t2biosystems.com/about-t2/
$TTOO
Wow. 14s today. DWAC‘d again. My oh my.
The big red slip slide from spring continues.
Yum. The SHMP Shrimp Scampi was done correctly. Another Lemonade on a hot afternoon was a perfect match. Wine later.
SHMP
$PCTL 21st-Century Energy Solutions and Future of H2S Removal
https://21st-centuryenergy.com/blog/natures-approach-to-h2s-reduction-harnessing-biological-methods/
21st-Century Energy, Inc. is a wholly-owned subsidiary of PCT Ltd.
$PCTL
$PCTL 21st-Century Energy Solutions and Future of H2S Removal
https://21st-centuryenergy.com/blog/natures-approach-to-h2s-reduction-harnessing-biological-methods/
21st-Century Energy, Inc. is a wholly-owned subsidiary of PCT Ltd.
$PCTL
$TTOO T2-Biosystems Regains Compliance with Nasdaq’s Market Value of Listed Securities Requirement
https://www.globenewswire.com/news-release/2022/11/01/2545498/32489/en/T2-Biosystems-Regains-Compliance-with-Nasdaq-s-Minimum-Bid-Price-Rule.html
LEXINGTON, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it received written notice from the NASDAQ Stock Market LLC (“NASDAQ”) on August 8, 2023 informing the Company that it has regained compliance with the market value of listed securities (“MVLS”) requirement, as set forth in Nasdaq Listing Rule 5550(b)(2) (the “Rule”) for continued listing on the NASDAQ Capital Market.
As previously reported, T2 Biosystems was notified by the NASDAQ on November 22, 2022 that it was not in compliance with the NASDAQ’s Capital Market requirement because it failed to maintain a MVLS of at least $35 million for a period of 30 consecutive business days. To regain compliance with the Rule, the Company was required to maintain a MVLS of at least $35 million for at least 10 consecutive trading days. This requirement was met on August 7, 2023, the tenth consecutive trading day when the MVLS was at least $35 million.
The Company must still demonstrate compliance with Listing Rule 5550(a)(2), the Bid Price Rule, by November 20, 2023.
About T2 Biosystems
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, the T2Bacteria® Panel, the T2Candida® Panel, the T2Resistance® Panel, and the T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including the T2Biothreat™ Panel, the Candida auris test, and T2Lyme™ Panel, as well as next-generation products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers. For more information, please visit www.t2biosystems.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements about the Company’s ability to regain compliance with the listing requirements of the Nasdaq Capital Market, including its ability to effect a reverse share split, as well as statements that include the words “expect,” “intend,” “plan”, “believe”, “project”, “forecast”, “estimate,” “may,” “should,” “anticipate,” and similar statements of a future or forward looking nature. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, (i) any inability to (a) realize anticipated benefits from commitments, contracts or products; (b) successfully execute strategic priorities; (c) bring products to market; (d) expand product usage or adoption; (e) obtain customer testimonials; (f) accurately predict growth assumptions; (g) realize anticipated revenues; (h) incur expected levels of operating expenses; or (i) increase the number of high-risk patients at customer facilities; (ii) failure of early data to predict eventual outcomes; (iii) failure to make or obtain anticipated FDA filings or clearances within expected time frames or at all; or (iv) the factors discussed under Item 1A. “Risk Factors” in the company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the U.S. Securities and Exchange Commission, or SEC, on March 31, 2023, and other filings the company makes with the SEC from time to time. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While the company may elect to update such forward-looking statements at some point in the future, unless required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. Thus, no one should assume that the Company’s silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing the company’s views as of any date subsequent to the date of this press release.
Investor Contact:
Philip Trip Taylor, Gilmartin Group
philip@gilmartinIR.com
415-937-5406
$TTOO
$TTOO T2-Biosystems Regains Compliance with Nasdaq’s Market Value of Listed Securities Requirement
https://www.globenewswire.com/news-release/2022/11/01/2545498/32489/en/T2-Biosystems-Regains-Compliance-with-Nasdaq-s-Minimum-Bid-Price-Rule.html
LEXINGTON, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it received written notice from the NASDAQ Stock Market LLC (“NASDAQ”) on August 8, 2023 informing the Company that it has regained compliance with the market value of listed securities (“MVLS”) requirement, as set forth in Nasdaq Listing Rule 5550(b)(2) (the “Rule”) for continued listing on the NASDAQ Capital Market.
As previously reported, T2 Biosystems was notified by the NASDAQ on November 22, 2022 that it was not in compliance with the NASDAQ’s Capital Market requirement because it failed to maintain a MVLS of at least $35 million for a period of 30 consecutive business days. To regain compliance with the Rule, the Company was required to maintain a MVLS of at least $35 million for at least 10 consecutive trading days. This requirement was met on August 7, 2023, the tenth consecutive trading day when the MVLS was at least $35 million.
The Company must still demonstrate compliance with Listing Rule 5550(a)(2), the Bid Price Rule, by November 20, 2023.
About T2 Biosystems
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, the T2Bacteria® Panel, the T2Candida® Panel, the T2Resistance® Panel, and the T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including the T2Biothreat™ Panel, the Candida auris test, and T2Lyme™ Panel, as well as next-generation products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers. For more information, please visit www.t2biosystems.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements about the Company’s ability to regain compliance with the listing requirements of the Nasdaq Capital Market, including its ability to effect a reverse share split, as well as statements that include the words “expect,” “intend,” “plan”, “believe”, “project”, “forecast”, “estimate,” “may,” “should,” “anticipate,” and similar statements of a future or forward looking nature. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, (i) any inability to (a) realize anticipated benefits from commitments, contracts or products; (b) successfully execute strategic priorities; (c) bring products to market; (d) expand product usage or adoption; (e) obtain customer testimonials; (f) accurately predict growth assumptions; (g) realize anticipated revenues; (h) incur expected levels of operating expenses; or (i) increase the number of high-risk patients at customer facilities; (ii) failure of early data to predict eventual outcomes; (iii) failure to make or obtain anticipated FDA filings or clearances within expected time frames or at all; or (iv) the factors discussed under Item 1A. “Risk Factors” in the company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the U.S. Securities and Exchange Commission, or SEC, on March 31, 2023, and other filings the company makes with the SEC from time to time. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While the company may elect to update such forward-looking statements at some point in the future, unless required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. Thus, no one should assume that the Company’s silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing the company’s views as of any date subsequent to the date of this press release.
Investor Contact:
Philip Trip Taylor, Gilmartin Group
philip@gilmartinIR.com
415-937-5406
$TTOO
$TTOO News: T2-Biosystems Receives FDA Breakthrough Device Designation for Candida Auris Diagnostic Test”
https://www.globenewswire.com/news-release/2023/07/20/2708188/32489/en/T2-Biosystems-Receives-FDA-Breakthrough-Device-Designation-for-Candida-Auris-Diagnostic-Test.html
LEXINGTON, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for the Company’s Candida auris (C. auris) direct-from-blood molecular diagnostic test.
This marks the third T2 Biosystems’ product to receive FDA Breakthrough Device designation, as the Company was previously granted FDA Breakthrough Device designation for its T2Resistance® Panel and T2Lyme™ Panel. The Company plans to expand the test menu on its FDA-cleared T2Dx® Instrument by adding the C. auris diagnostic test that is designed to detect C. auris species directly from blood in just 3-5 hours, without the need to wait days for a positive blood culture.
"We are pleased with the FDA’s decision to grant Breakthrough Device designation for our Candida auris test, which provides greater and more frequent access to the FDA and may accelerate our path to FDA clearance,” stated John Sperzel, Chairman and CEO of T2 Biosystems. “We believe adding Candida auris to the test menu on our FDA-cleared T2Dx Instrument will provide clinicians with a valuable tool to rapidly detect a dangerous, multidrug-resistant fungal pathogen much faster than blood culture-based methods, strengthening our value proposition and increasing the attractiveness of our products to U.S. hospitals.”
Candida auris is a multidrug-resistant fungal pathogen recognized as a serious global health threat with a mortality rate of up to 60%, and is difficult to identify with standard laboratory methods, which can lead to inappropriate treatment. The CDC estimates the costs associated with U.S. fungal diseases, in general, are as high as $48 billion annually, and has called on public health professionals to help lower the burden of fungal disease by continuing to raise awareness of the life-saving benefits of early detection and proper treatment.
The Company currently markets and sells the T2Candida® Panel, the only FDA-cleared diagnostic test able to detect sepsis-causing fungal pathogens directly from blood, without the need to wait days for a positive blood culture. The T2Candida Panel runs on the fully-automated T2Dx Instrument and simultaneously detects five Candida species, including Candida albicans, Candida tropicalis, Candida parapsilosis, Candida krusei, and Candida glabrata. Rapid detection of these pathogens, as well as Candida auris, is essential to getting infected patients on appropriate antifungal therapy and improving clinical outcomes.
About FDA Breakthrough Devices Program
The FDA Breakthrough Devices Program is a voluntary program for certain medical devices and device-led combination products that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. It is available for devices and device-led combination products which are subject to review under a premarket approval application (PMA), premarket notification (510(k)), or De Novo classification request (De Novo request). This program is intended to help patients have more timely access to these medical devices by expediting their development, assessment, and review, while preserving the statutory standards for PMA approval, 510(k) clearance, and De Novo marketing authorization, consistent with the FDA’s mission to protect and promote public health. For more information, please visit:
https://www.fda.gov/media/108135/download.
About T2 Biosystems
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, the T2Bacteria® Panel, the T2Candida® Panel, the T2Resistance® Panel, and the T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including the T2Biothreat™ Panel, the Candida auris test, and T2Lyme™ Panel, as well as next-generation products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers. For more information, please visit www.t2biosystems.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the potential that the Breakthrough Device designation will accelerate the FDA clearance of the Candida auris test or the Company’s commercialization of the Candida auris test, the ability of the Candida auris test to successfully detect Candida auris, as well as statements that include the words “expect,” “may,” “should,” “anticipate,” and similar statements of a future or forward-looking nature. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, (i) any inability to (a) realize anticipated benefits from commitments, contracts or products; (b) successfully execute strategic priorities; (c) bring products to market; (d) expand product usage or adoption; (e) obtain customer testimonials; (f) accurately predict growth assumptions; (g) realize anticipated revenues; (h) incur expected levels of operating expenses; or (i) increase the number of high-risk patients at customer facilities; (ii) failure of early data to predict eventual outcomes; (iii) failure to make or obtain anticipated FDA filings or clearances within expected time frames or at all; or (iv) the factors discussed under Item 1A. “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the U.S. Securities and Exchange Commission, or SEC, on March 31, 2023, and other filings the Company makes with the SEC from time to time, including our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, unless required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. Thus, no one should assume that the Company’s silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.
Investor Contact:
Philip Trip Taylor, Gilmartin Group
ir@T2Biosystems.com
415-937-5406
$TTOO News: T2-Biosystems Receives FDA Breakthrough Device Designation for Candida Auris Diagnostic Test”
https://www.globenewswire.com/news-release/2023/07/20/2708188/32489/en/T2-Biosystems-Receives-FDA-Breakthrough-Device-Designation-for-Candida-Auris-Diagnostic-Test.html
LEXINGTON, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for the Company’s Candida auris (C. auris) direct-from-blood molecular diagnostic test.
This marks the third T2 Biosystems’ product to receive FDA Breakthrough Device designation, as the Company was previously granted FDA Breakthrough Device designation for its T2Resistance® Panel and T2Lyme™ Panel. The Company plans to expand the test menu on its FDA-cleared T2Dx® Instrument by adding the C. auris diagnostic test that is designed to detect C. auris species directly from blood in just 3-5 hours, without the need to wait days for a positive blood culture.
"We are pleased with the FDA’s decision to grant Breakthrough Device designation for our Candida auris test, which provides greater and more frequent access to the FDA and may accelerate our path to FDA clearance,” stated John Sperzel, Chairman and CEO of T2 Biosystems. “We believe adding Candida auris to the test menu on our FDA-cleared T2Dx Instrument will provide clinicians with a valuable tool to rapidly detect a dangerous, multidrug-resistant fungal pathogen much faster than blood culture-based methods, strengthening our value proposition and increasing the attractiveness of our products to U.S. hospitals.”
Candida auris is a multidrug-resistant fungal pathogen recognized as a serious global health threat with a mortality rate of up to 60%, and is difficult to identify with standard laboratory methods, which can lead to inappropriate treatment. The CDC estimates the costs associated with U.S. fungal diseases, in general, are as high as $48 billion annually, and has called on public health professionals to help lower the burden of fungal disease by continuing to raise awareness of the life-saving benefits of early detection and proper treatment.
The Company currently markets and sells the T2Candida® Panel, the only FDA-cleared diagnostic test able to detect sepsis-causing fungal pathogens directly from blood, without the need to wait days for a positive blood culture. The T2Candida Panel runs on the fully-automated T2Dx Instrument and simultaneously detects five Candida species, including Candida albicans, Candida tropicalis, Candida parapsilosis, Candida krusei, and Candida glabrata. Rapid detection of these pathogens, as well as Candida auris, is essential to getting infected patients on appropriate antifungal therapy and improving clinical outcomes.
About FDA Breakthrough Devices Program
The FDA Breakthrough Devices Program is a voluntary program for certain medical devices and device-led combination products that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. It is available for devices and device-led combination products which are subject to review under a premarket approval application (PMA), premarket notification (510(k)), or De Novo classification request (De Novo request). This program is intended to help patients have more timely access to these medical devices by expediting their development, assessment, and review, while preserving the statutory standards for PMA approval, 510(k) clearance, and De Novo marketing authorization, consistent with the FDA’s mission to protect and promote public health. For more information, please visit:
https://www.fda.gov/media/108135/download.
About T2 Biosystems
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, the T2Bacteria® Panel, the T2Candida® Panel, the T2Resistance® Panel, and the T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including the T2Biothreat™ Panel, the Candida auris test, and T2Lyme™ Panel, as well as next-generation products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers. For more information, please visit www.t2biosystems.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the potential that the Breakthrough Device designation will accelerate the FDA clearance of the Candida auris test or the Company’s commercialization of the Candida auris test, the ability of the Candida auris test to successfully detect Candida auris, as well as statements that include the words “expect,” “may,” “should,” “anticipate,” and similar statements of a future or forward-looking nature. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, (i) any inability to (a) realize anticipated benefits from commitments, contracts or products; (b) successfully execute strategic priorities; (c) bring products to market; (d) expand product usage or adoption; (e) obtain customer testimonials; (f) accurately predict growth assumptions; (g) realize anticipated revenues; (h) incur expected levels of operating expenses; or (i) increase the number of high-risk patients at customer facilities; (ii) failure of early data to predict eventual outcomes; (iii) failure to make or obtain anticipated FDA filings or clearances within expected time frames or at all; or (iv) the factors discussed under Item 1A. “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the U.S. Securities and Exchange Commission, or SEC, on March 31, 2023, and other filings the Company makes with the SEC from time to time, including our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, unless required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. Thus, no one should assume that the Company’s silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.
Investor Contact:
Philip Trip Taylor, Gilmartin Group
ir@T2Biosystems.com
415-937-5406
$TTOO T2-Biosystems: Enhancing Sepsis Care in the Emergency Department with Faster Diagnostics
>>> https://learn.sepsis.org/SepsisAllianceSummit2023
>>> Sepsis Alliance Summit | September 27 - 28, 2023
Agenda: 12:10-12:25 | T2 Biosystems Sponsored Session: Enhancing Sepsis Care in the Emergency Department with Faster Diagnostics
Conference: This September, Sepsis Alliance is proudly hosting its Sepsis Alliance Summit. Set to coincide with Sepsis Awareness Month, the event will feature two days of learning and inspiration for healthcare professionals across the continuum of care, including nurses, physicians, pharmacists, allied health professionals, data/quality/safety/IT professionals, students, leadership, policy makers, and industry leaders.
Designed to explore an array of sepsis-related topics in healthcare, the Sepsis Alliance Summit will include expert presentations from clinicians, innovation experts, and other influential leaders. Join the sessions that are relevant to your practice and interests, and increase your sepsis knowledge and skills. We encourage you to attend sessions live, as speakers will be present to answer questions and share knowledge for most sessions. If you are unable to attend live, sessions will be prerecorded and available at a later time.
$TTOO